When did apotex's ruxolitinib gain usa approval?

Apotex’s generic ruxolitinib was approved by the U.S. Food and Drug Administration on March 27, 2023. The approval marked the first time a non‑brand name version of the drug (originally marketed by Janssen as Jakafi) became available for use in the United States. The FDA cleared it for the same indications as the brand—primarily myelofibrosis and graft‑versus‑host disease—allowing patients and clinicians to choose the more affordable generic option.